Cambrex, a global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, announced that their stability storage business, Q1 Scientific, has opened a new 20,000 sq. ft. cGMP facility in Belgium, expanding its capacity for environmentally controlled stability storage services to the pharmaceutical, medical device and life sciences industries across Europe.

Strategically located in the Liège region and approximately 90 kilometers from Brussels, the new state-of-the-art temperature-controlled and monitored storage facility provides 35,000 temperature-controlled storage spaces for all key ICH climatic zones, including long-term, intermediate, and accelerated stability trials including 2-8°C, 25°C / 60%RH and 40°C / 75%RH.

“Following our acquisition of Q1 Scientific in June 2022, we have continued to see an increase in demand for stability storage services,” said Tom Loewald, CEO, Cambrex. “This expansion provides easily accessible capacity in continental Europe, as well as flexibility to react quickly and effectively to customers’ changing requirements.”

From this new location, Q1 Scientific will serve pharmaceutical companies across Europe under the leadership of the new Belgium general manager, Cécile Jacoby.

Stephen Delaney, managing director of Q1 Scientific said, “Opening in Belgium is a significant milestone for Q1 Scientific and we are excited to be adding to our fast-growing stability storage business. Operating two sites will be a great benefit to our European customers, who can now expect greater temperature-controlled transport options in mainland Europe.”

The expansion into Belgium complements Q1 Scientific’s existing footprint in Waterford, Ireland, and is consistent with Cambrex’s strategy to expand its portfolio of specialized solutions for pharmaceutical development and manufacturing across North America and Europe.